くすりのしおり

Injection
Revised: 3/2019

The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.
Brand name :
TEMODAL Infusion 100mg
 Active ingredient:
Temozolomide
 Dosage form:
injection
 Print on wrapping:

Effects of this medicine

This medicine suppresses tumor cell growth and shows anticancer effect.
It is usually used to treat malignant glioma and recurrent or refractory Ewing's sarcoma.

Before using this medicine, be sure to tell your doctor and pharmacist

  • If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
    If you have: bleeding tendency, renal disorder, liver disorder, infectious diseases or varicella.
  • If you are pregnant, possibly pregnant or breastfeeding.
  • If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)

Dosing schedule (How to take this medicine)

  • Your dosing schedule prescribed by your doctor is ((        to be written by a healthcare professional))
  • In general, administer by intravenous infusion over 90 minutes at a time.
    For treatment of newly-diagnosed malignant glioma: Concomitantly with radiotherapy, in general, for adults, administer once a day, for 42 days, and withdraw the medication for 4 weeks. After the above-described course, in administration of Temodal alone, administer once a day, for 5 days, and withdraw the medication for 23 days. This 28-day is defined as one course.
    For treatment of recurrent malignant glioma: In general, for adults, administer once a day, for 5 days, and withdraw the medication for 23 days. This 28-day is defined as one course.
    For treatment of recurrent or refractory Ewing's sarcoma: Concomitantly with irinotecan, in general, administer once a day, for consecutive 5 days, and withdraw the medication for 16 days or longer. This is defined as one course and this treatment course is repeated.
  • Ask the doctor about the treatment span.

Precautions while taking this medicine

  • Follow the instructions of your doctor and receive a blood test regularly.

Possible adverse reactions to this medicine

The most commonly reported adverse reactions include malaise, headache, anemia, nausea, vomiting, loss of appetite, constipation, diarrhea and fatigue. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
  • anemic symptom, fever, bleeding tendency [myelosuppression]
  • fever, cough, phlegm [Pneumocystis pneumonia, infectious diseases]
  • fever, dry cough, breathing difficulty [interstitial pneumonia]
  • headache, vomiting, hemiplegia [cerebral bleeding]
  • breathing difficulty, hives, swelling around the eyes or lips [anaphylaxis]
  • general malaise, loss of appetite, yellow discoloration of skin and/or conjunctiva [liver dysfunction, jaundice]
  • fever, red rash with dropsical swelling in the center, bloodshot eyes [toxic epidermal necrolysis, Stevens-Johnson syndrome]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.

Storage conditions and other information

For healthcare professional use only : Day Month Year

For further information, talk to your doctor or pharmacist.